Loading stock data…
ACOG
$6.00-0.02 (-0.33%)
After Hours$6.00+0.00 (+0.00%)· Last close Jun 9
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Alpha Cognition Inc. Common Stock in the Healthcare sector is trading at $6.00 with a market capitalization of $132M. Wall Street consensus targets $14.67 (3 analysts), implying a +144.4% move over the next 12 months. The stock is currently 48% below its 52-week high of $11.54, remaining 5.8% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +144.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$6.00
Potential Downside
0%
Whystock Fair Value$6.00
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$14.67+144.4%
Range$12.00 – $18.00
Fundamentals
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tab...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$132.39M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-43.76%
Volume
Today's trading volume
92,081
Recent News
Alpha Cognition Inc. (NASDAQ:ACOG) Just Reported, And Analysts Assigned A US$16.00 Price Target
Last week saw the newest first-quarter earnings release from Alpha Cognition Inc. ( NASDAQ:ACOG ), an important...
Alpha Cognition Inc. Common Stock Q1 2026 Earnings Call Summary
Moby summary of Alpha Cognition Inc. Common Stock's Q1 2026 earnings call
Alpha Cognition Q1 Earnings Call Highlights
Alpha Cognition (NASDAQ:ACOG) reported 40% sequential revenue growth in the first quarter of 2026, as executives said commercial adoption of its Alzheimer’s treatment ZUNVEYL continued to build across prescribers and long-term care facilities. Chief Executive Officer Michael McFadden said the quart
Alpha Cognition Inc. (ACOG) Reports Q1 Loss, Tops Revenue Estimates
Alpha Cognition Inc. (ACOG) delivered earnings and revenue surprises of +8.64% and +4.40%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Alpha Cognition Inc. (ACOG) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Alpha Cognition Inc. (ACOG) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.